Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
10:55am, Tuesday, 06'th Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 234.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the pos
REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript
11:06pm, Thursday, 01'st Aug 2024
REGENXBIO Inc. (NASDAQ:RGNX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Patrick Christmas - CLO Curran Simpson - President and CEO Steve Pakola - CMO Vit Vasista
Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
06:47pm, Thursday, 01'st Aug 2024
Regenxbio (RGNX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.29. This compares to loss of $1.66 per share a year ago.
REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
04:05pm, Thursday, 01'st Aug 2024
Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025) New, positive data from
REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
07:03am, Thursday, 01'st Aug 2024
Robust microdystrophin expression observed in new data from pivotal dose Patients aged 5.8 and 8.5 years at dosing had expression levels at 77.2% and 46.5% of control, respectively Consistent high exp
REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
07:05am, Thursday, 25'th Jul 2024
ROCKVILLE, Md. , July 25, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m.
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
11:02am, Friday, 12'th Jul 2024
Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
05:35am, Tuesday, 25'th Jun 2024
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i
7 Biotech Stocks to Buy on the Dip: June 2024
12:56pm, Monday, 24'th Jun 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
07:05am, Monday, 24'th Jun 2024
Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad label End-of-Phase II meeting with FDA scheduled for late
Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval pathway expected to start in Q3 2024 Confirmatory trial expected to begin in H2
REGENXBIO Announces Leadership Transition
07:05am, Wednesday, 12'th Jun 2024
Curran Simpson, Chief Operating Officer, Appointed as President and CEO Co-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md.
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
11:55pm, Monday, 10'th Jun 2024
REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related ma
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
07:05am, Wednesday, 05'th Jun 2024
ROCKVILLE, Md. , June 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 202
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Friday, 10'th May 2024
ROCKVILLE, Md. , May 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: BofA Securities Health Care Conference 2
